328 related articles for article (PubMed ID: 18472232)
1. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
Biglia N; Mariani L; Ponzone R; Sismondi P
Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
[No Abstract] [Full Text] [Related]
2. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
[TBL] [Abstract][Full Text] [Related]
3. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
Haldar K; Crawford R
Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
[No Abstract] [Full Text] [Related]
4. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
5. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
Kenkhuis MJ; de Bock GH; Elferink PO; Arts HJ; Oosterwijk JC; Jansen L; Mourits MJ
Maturitas; 2010 Jul; 66(3):310-4. PubMed ID: 20409655
[TBL] [Abstract][Full Text] [Related]
6. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
[TBL] [Abstract][Full Text] [Related]
7. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
8. Risk reduction works for BRCA mutation carriers--with heavy costs.
Vanchieri C
J Natl Cancer Inst; 2005 Jul; 97(14):1032-3. PubMed ID: 16030299
[No Abstract] [Full Text] [Related]
9. [Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].
Pujol P; This P; Noruzinia M; Stoppa-Lyonnet D; Maudelonde T
Bull Cancer; 2004; 91(7-8):583-91. PubMed ID: 15381448
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers.
Chapman JS; Powell CB; McLennan J; Crawford B; Mak J; Stewart N; Chen LM
Gynecol Oncol; 2011 Aug; 122(2):339-43. PubMed ID: 21531449
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
Haber D
N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
[No Abstract] [Full Text] [Related]
12. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
[No Abstract] [Full Text] [Related]
13. CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much?
Bradford LS; Schorge JO
Menopause; 2011 Feb; 18(2):123-4. PubMed ID: 21191312
[No Abstract] [Full Text] [Related]
14. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
Powell CB
Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
[No Abstract] [Full Text] [Related]
15. Oophorectomy in carriers of BRCA mutations.
Whitfield GA
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353513
[No Abstract] [Full Text] [Related]
16. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B
Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Mahajan NN
Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078
[No Abstract] [Full Text] [Related]
18. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy.
ACOG
Obstet Gynecol; 2008 Jan; 111(1):231-41. PubMed ID: 18165419
[No Abstract] [Full Text] [Related]
19. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic oophorectomy and hormone replacement therapy: protection at what price?
Garber JE; Hartman AR
J Clin Oncol; 2004 Mar; 22(6):978-80. PubMed ID: 14981100
[No Abstract] [Full Text] [Related]
[Next] [New Search]
